Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

December 30, 2026

Conditions

Stomach NeoplasmsDigestive System NeoplasmsNeoplasmsDigestive System DiseasesStomach DiseasesNeoplasms by Site

Interventions

DRUG

Camrelizumab

200mg, intravenously, d1

DRUG

SOX

SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)

PROCEDURE

Surgery

Trial Locations (1)

The Second Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors

lead

The Second Affiliated Hospital of Fujian Medical University

OTHER